QX004N
Psoriasis, Crohn's Disease
Phase 2Active
Key Facts
About Qyuns Therapeutics
Publicly traded biotech developing antibody therapies for autoimmune and allergic diseases with a pipeline targeting IL-4Rα, IL-17A, IL-23, and TSLP pathways.
View full company profileTherapeutic Areas
Other Psoriasis, Crohn's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Bmab 1500 (Ustekinumab biosimilar) | Biocon | Phase III |